IO Biotech to participate in panel discussion at Biotech Showcase in San Francisco on January 7th

Jan 5, 2019

Copenhagen, Denmark – January 5, 2019: IO Biotech’s CEO, Mai-Britt Zocca, is to participate in the panel discussion “Investing in Next Gen Immunotherapies: Moving the Checkpoint Inhibitors to the Next Level” at Biotech Showcase in San Francisco on January 7, 2019 during the JPM week.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

November 9, 2021

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

September 14, 2021

back to news overview